Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government

Executive Summary

Having suddenly resigned from the UK government, Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.

You may also be interested in...



UK R&D Centre for Antimicrobial Resistance Goes Into Battle

The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.

13 Pharmas Sign Roadmap For Antibiotic Reform – But What Do They Want?

More than 13 global pharma companies, including GlaxoSmithKline, Pfizer and Merck & Co., have agreed a "Roadmap" aimed at relieving the growing antimicrobial resistance crisis worldwide – as well as principles to explore alternative business models and incentives for antibiotic R&D and reimbursement.

UN Countries Make Bold Pledges On AMR, Including Funding For R&D Into New Drugs and Diagnostics

During the high-level UN meeting on Sept. 21, all 193 member countries will sign a declaration in which they pledge to take concrete action on tackling antimicrobial resistance, including providing resources for research into new drugs, vaccines and diagnostics, and ensuring good stewardship of antibiotic use in both humans and animals.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel